Since PARPi were approved by the FDA and EMA as a therapeutic strategy for advanced BRCA1/2-mutant breast cancer, the resistance to PARPi has been the principal obstacle limiting the clinical use in TNBC (140). Here, BRCA1 is linked to breast cancer.